US 12,264,146 B2
Rho kinase inhibitor, method for preparing same and uses thereof
Baoxian Zhang, Beijing (CN); Hongwu Zhang, Beijing (CN); Jie Hu, Beijing (CN); Zhiyun Kang, Beijing (CN); Chunmei Xue, Beijing (CN); Wenhui Li, Beijing (CN); Yanwei Song, Beijing (CN); Zhenzhen Wu, Beijing (CN); Anping Chen, Beijing (CN); Fang Wang, Beijing (CN); Hengchun Ren, Beijing (CN); and Jun Li, Beijing (CN)
Assigned to Beijing Increase Innovative Drug Co., LTD, Beijing (CN)
Appl. No. 17/290,045
Filed by BEIJING INCREASE INNOVATIVE DRUG CO., LTD., Beijing (CN)
PCT Filed May 6, 2019, PCT No. PCT/CN2019/085689
§ 371(c)(1), (2) Date Apr. 29, 2021,
PCT Pub. No. WO2020/087901, PCT Pub. Date May 7, 2020.
Claims priority of application No. 201811275571.0 (CN), filed on Oct. 30, 2018.
Prior Publication US 2022/0002265 A1, Jan. 6, 2022
Int. Cl. C07D 401/12 (2006.01); A61P 9/10 (2006.01)
CPC C07D 401/12 (2013.01) [A61P 9/10 (2018.01)] 17 Claims
 
1. A compound represented by Formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof,

OG Complex Work Unit Chemistry
wherein, X is hydrogen, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;
R is hydroxyl, CH3 (CH2)mO—, CH3 (CH2)nCOO— r HCO—; m and n are each independently 0, 1, 2, 3; and
R1 is C1 to C5 chain alkyl or C3 to C6 cycloalkyl.